Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Share-based Compensation (2016 - 2025)

Cumberland Pharmaceuticals' Share-based Compensation history spans 16 years, with the latest figure at $172160.0 for Q4 2025.

  • For Q4 2025, Share-based Compensation rose 130.12% year-over-year to $172160.0; the TTM value through Dec 2025 reached $408320.0, up 35.25%, while the annual FY2025 figure was $408320.0, 35.25% up from the prior year.
  • Share-based Compensation for Q4 2025 was $172160.0 at Cumberland Pharmaceuticals, up from $81262.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $224786.0 in Q4 2021 and bottomed at -$27753.0 in Q2 2022.
  • The 5-year median for Share-based Compensation is $90156.0 (2023), against an average of $117043.6.
  • The largest annual shift saw Share-based Compensation plummeted 114.46% in 2022 before it soared 130.12% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $224786.0 in 2021, then plummeted by 43.54% to $126905.0 in 2022, then decreased by 28.96% to $90156.0 in 2023, then decreased by 17.02% to $74812.0 in 2024, then soared by 130.12% to $172160.0 in 2025.
  • Per Business Quant, the three most recent readings for CPIX's Share-based Compensation are $172160.0 (Q4 2025), $81262.0 (Q3 2025), and $80686.0 (Q2 2025).